美国专利重复授权审查标准研究及对我国的启示  

The examination standard of double patenting in the U.S. and its implications on China

作　　者：丁锦希[1] 詹来明[1] 

机构地区：[1]中国药科大学医药知识产权研究所,南京211198

出　　处：《上海医药》2014年第11期49-53,共5页Shanghai Medical & Pharmaceutical Journal

基　　金：2013年度国家社会科学基金资助项目(No.13BFX120);项目名称:

摘　　要：通过分析美国近期发生的"Lilly vs Teva"生物医药专利重复授权纠纷案,深入研究美国专利重复授权的审查标准,在此基础上讨论我国目前重复授权的审查标准,指出存在的问题及可能带来的一些不利影响。最后结合美国重复授权审查标准,对我国重复授权审查标准的完善提出建议。The examination standard for double patenting in the U.S. was deeply studied by analyzing the bio-pharmaceutical patent disputes concerning double patenting between Eli Lilly and Teva. On this basis, the examination standard of double patenting in China was discussed and the problems and possible adverse impact were also pointed out. And ifnally, several pieces of reasonable suggestions were proposed so as to complete Chinese examination standard of double patenting based on that in the U.S..

关 键 词：抵触申请 重复授权 非显而易见性 审查标准 

分 类 号：D971.2[政治法律—法学] DD913